Role and mechanism of vaspin in diabetic cardiomyopathy
(2.Department of Cardiology, the Third Hospital of Wuhan City, Wuhan, Hubei Province, China 430000)
(3.Department of Cardiology, Jiangxi Provincial People’s Hospital, Nanchang, Jiangxi Province, China 330006)
【Abstract】Aim To observe the effects of vaspin on myocardial fibrosis and cardiac function in diabetic cardiomyopathy (DCM) rats. Methods Male SD rats were divided randomly into three groups: control group, DCM group, and vaspin group. Rats in control group were simply treated with normal saline (0.5 mL·kg−1·d−1) and those in vaspin group were injected intraperitoneally with vaspin (320 ng·kg−1·d−1) solution daily for 12 weeks after diabetes was developed. Then the following experiments were performed: Echocardiography to assess left ventricular ejection fraction (LVEF), fractional shortening (FS), left ventricular end-diastole diameter (LVIDd), left ventricular end-systolic diameter (LVIDs) and Em/Am; ELISA to measure serum TNF-α concentration; Masson’s trichrome method to assess cardiac fibrosis and analyze collagen volume fraction (CVF); Western blot to examine the expressions of LC3, Beclin-1, P62, Bax, Bcl-2, TGF-β1 and collagen I in the myocardium. Results As for TNF-α levels, there was no statistically significant difference between DCM group and vaspin group, or statistically significant difference between DCM and control group. Echocardiography performed to assess the effect of vaspin on cardiac function showed that LVEF and FS levels were decreased in DCM group while increased in vaspin group. The ratio of Em/Am was decreased in DCM group but was not improved in vaspin group. Western blot showed that LC3-II/LC3-I ratio and Beclin-1 expression decreased and P62 expression increased in DCM group, which were reversed by vaspin treatment. Compared with DCM group, collagen deposition in vaspin group decreased. Western blot suggested that vaspin could reduce the expression of collagen I, but had no significant effect on the expression of TGF-β1. Conclusion Vaspin increases the level of autophagy and could ameliorate myocardial fibrosis and cardiac function in rats with diabetic cardiomyopathy.
【Keywords】 vaspin; autophagy; fibrosis; DCM; apoptosis; oxidative stress;
 Rubler S, Dlugash J, Yuceoglu Y Z, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis [J]. Am J Cardiol, 1972, 30 (6): 595–602.
 Bluher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance [J]. Endocrine, 2012, 41 (2): 176–82.
 Motawi T, Mahdy S G, El-Sawalhi M M, et al. Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis [J]. Can J Physiol Pharmacol, 2018, 96 (1): 38–44.
 Yang W, Li Y, Tian T, et al. Serum vaspin concentration in elderly patients with type 2 diabetes mellitus and macrovascular complications [J]. BMC Endocr Disord, 2017, 17 (1): 67.
 Qi D, Wang D, Zhang C, et al. Vaspin protects against LPS-induced ARDS by inhibiting inflammation, apoptosis and reactive oxygen species generation in pulmonary endothelial cells via the Akt/GSK3beta pathway [J]. Int J Mol Med, 2017, 40 (6): 1803–17.
 Sun N, Wang H, Wang L. Vaspin alleviates dysfunction of endothelial progenitor cells induced by high glucose via PI3K/Akt/eNOS pathway [J]. Int J Clin Exp Pathol, 2015, 8 (1): 482–9.
 Lin Y, Zhuang J, Li H, et al. Vaspin attenuates the progression of atherosclerosis by inhibiting ER stress-induced macrophage apoptosis in apoE/mice [J]. Mol Med Rep, 2016, 13 (2): 1509–16.
 Xu X, Kobayashi S, Chen K, et al. Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes [J]. J Biol Chem, 2013, 288 (25): 18077–92.
 Xie Z, He C, Zou M H. AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy [J]. Autophagy, 2011, 7 (10): 1254–5.
 Xie Z, Lau K, Eby B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice [J]. Diabetes, 2011, 60 (6): 1770–8.
 Zhang L, Ding W Y, Wang Z H, et al. Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy [J]. J Transl Med, 2016, 14 (1): 109.
 Sun X H, Yin M S, Mu Y L. Alterations of mTOR pathway and autophagy in early type 2 diabetic cardiomyopathy in rats [J]. Chin J Pathol, 2016, 45 (10): 707–10 (in Chinese).
 Wang Y, Wang Y G, Ma Z C, et al. Ophiopogonin D attenuates angiotensin Ⅱ-induced myocardial hypertrophy by reducing autophagy [J]. Chin Pharmacol Bull, 2016, 32 (10): 1370–6 (in Chinese).
 Yang L, Li P, Fu S, et al. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance [J]. Cell Metab, 2010, 11 (6): 467–78.
 Codogno P, Meijer A J. Autophagy: a potential link between obesity and insulin resistance [J]. Cell Metab, 2010, 11 (6): 449–51.
 Zhang J, Gu X, Huang W Y, et al. The protective effect of glucogon like peptide-1 on H9C2 cardimyocytes against AGEs-induced injury by inhibiting excessive autophagy [J]. Chin Pharmacol Bull, 2017, 33 (3): 348–53 (in Chinese).